Edesa Biotech Director Carlo Sistilli Receives 19,000 Restricted Share Units

This Form 4 filing reports that Carlo Sistilli, a director of Edesa Biotech, Inc., received 19,000 restricted share units on May 27, 2026. The shares were granted at $0 per share as compensation under the company's 2019 Equity Incentive Compensation Plan. The restricted share units will vest in equal proportions over twelve months starting from the grant date. Following this transaction, Sistilli directly owns 49,417 common shares. Additionally, the filing discloses that Sistilli has an indirect ownership interest in 522 common shares held by York-Cav Enterprises, Inc., a company he partially owns, though he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest. The filing was signed by Peter J. Weiler as attorney-in-fact for Carlo Sistilli on May 29, 2026.